These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 38158924)
21. Mineralcorticoid receptor blockers in chronic kidney disease. Erraez S; López-Mesa M; Gómez-Fernández P Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451 [TBL] [Abstract][Full Text] [Related]
22. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. Georgianos PI; Agarwal R Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811 [TBL] [Abstract][Full Text] [Related]
23. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Lv R; Xu L; Che L; Liu S; Wang Y; Dong B Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374 [TBL] [Abstract][Full Text] [Related]
25. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease. Kim DL; Lee SE; Kim NH Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650 [TBL] [Abstract][Full Text] [Related]
26. Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM. Long A; Salvo M Ann Pharmacother; 2022 Sep; 56(9):1041-1048. PubMed ID: 35021925 [TBL] [Abstract][Full Text] [Related]
27. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. Kolkhof P; Joseph A; Kintscher U Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222 [TBL] [Abstract][Full Text] [Related]
28. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD. Mårup FH; Peters CD; Christensen JH; Birn H BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442 [TBL] [Abstract][Full Text] [Related]
29. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL; Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131 [TBL] [Abstract][Full Text] [Related]
30. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease. Górriz JL; González-Juanatey JR; Facila L; Soler MJ; Valle A; Ortiz A Nefrologia (Engl Ed); 2023; 43(4):386-398. PubMed ID: 37813743 [TBL] [Abstract][Full Text] [Related]
31. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Remuzzi G; Perico N; Macia M; Ruggenenti P Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578 [TBL] [Abstract][Full Text] [Related]
32. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508 [TBL] [Abstract][Full Text] [Related]